Medical Pharmacology Chapter 33-34: Cancer Chemotherapy Mitomycin

Mitomycin: clinical utility
1. Commonly used
2. Potentially curative in treating anal cancer
3. Both
4. Neither
Clinical approaches historically or currently associated with management of anal cancer:
1. Abdominal Perineal Resection (APR)
2. Combination of pelvic radiation and Chemotherapy before surgical resection associated with both pathologic complete response and survival.
3. Both
4. Neither
Agent(s) used along with mitomycin in treating anal cancer.
1. 5-FU (5-Flurouracil)
2. Cisplatin
3. Both
4. Neither
Mitomycin clinical use(s):
1. Treating anal cancer
2. Treating superficial transitional bladder cell carcinoma by direct installation into the bladder.
3. Both
4. Neither
Mitomycin in off-label use may be applied to the eye (drops) is an inhibitor of wound healing in order to decrease scarring.
1. True
2. False
Mitomycin pharmacology and pharmacokinetics:
1. Mitomycin is usually given orally.
2. Half-life of mitomycin ranges from about 25-90 minutes
3. Mitomycin appears concentrated in the central nervous system (CNS)
4. A & B
5. B & C
6. A, B & C
Mitomycin metabolism and excretion:
1. Mitomycin is primarily metabolized by the liver.
2. The active compound is minimally excreted in the bile in urine (<10%)
3. Both
4. Neither
Primary toxic effect of mitomycin:
1. Renal toxicity
2. Cardiotoxicity
3. Myelosuppression
4. All of the above side effects occur with about equal frequency
Other than myelosuppression, mitomycin side effects include:
1. Interstitial pneumonia
2. Neurological effects
3. Nausea and vomiting
4. All of the above
Mitomycin may enhance doxorubicin cardiotoxicity.
1. True
2. False